Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 5/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11672711 | 1.00 | LMNA (0.71) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL11860032 | 1.00 | LMNA (0.71) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL11861850 | 0.92 | LMNA (0.69) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL16937721 | 0.91 | LMNA (0.71) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL11854711 | 0.91 | LMNA (0.67) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL11854716 | 0.91 | LMNA (0.67) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL11856567 | 0.90 | HRH3 (0.59) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL11856182 | 0.89 | LMNA (0.65) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL11858790 | 0.89 | LMNA (0.67) | LMNAHSD17B10SMN1; SMN2MAPTRECQL | |
| SCHEMBL5164676 | 0.86 | ESR2 (0.70) | LMNAHSD17B10SMN1; SMN2MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1772462-A2 | Steroid sulfamates, method for the production and use thereof | Sterix Limited (GB) | 2007-04-11 | — | — | EP | disclosed |
| EP-0970104-B1 | STEROID SULFAMATES, METHOD FOR THE PRODUCTION AND USE THEREOF | STERIX LTD (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20050020695-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| US-6794409-B2 | HOMOSTEROIDS SUCH AS 17-CHLORO-17A-ALPHA-ETHINYL-17A, 18A-DIHOMO-ESTRA-1,3,5(10),16-TETRAENE-3,17A BETA-DIOL; WITHOUT USE OF PROGESTIN; CONTRACEPTION; FOR TREATMENT OF PROLIFERATIVE DISEASES OF THE OVARY | SCHERING AG (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | US | disclosed |
| WO-2002068548-A9 | USE OF ERSS-SELECTIVE LIGANDS FOR REGULATING FERTILITY AND COMPOUNDS USEFUL THEREFORE | SCHERING AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| US-6339079-B1 | FOR THERAPY AND DIAGNOSIS OF ESTROGEN-DEPENDENT TUMORS | ID PHARMA GMBH (DE) | 2002-01-15 | — | — | US | disclosed |
| US-3971809-A | 3A,4,7,7A-Tetrahydro-4-phenylethyl-7a-alkyl-5(6H)-indanones and process for the preparation thereof | HOFFMANN-LA ROCHE INC. (US) | 1976-07-27 | — | — | US | disclosed |
| US-3959322-A | Synthesis of 13-alkyl-gon-4-ones | Smith, Herchel (US) | 1976-05-25 | — | — | US | disclosed |
| US-3933870-A | Synthesis of A-ring aromatic steroids | HOFFMANN-LA ROCHE INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESRRB, ESR2 | LMNA 4408/4885HSD17B10 716/4885SMN1; SMN2 4874/4885 |
| US-20050020695-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESR2, ESRRB | LMNA 4313/4885HSD17B10 793/4885SMN1; SMN2 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.